French healthcare company Sanofi SA (Euronext Paris:SAN) (Nasdaq:SNY) reported on Friday a 2.6% increase in sales to EUR10.7bn for the fourth quarter of 2022.
The year-on-year improvement was driven by Sanofi's asthma and eczema drug Dupixent, which saw sales growth of 42.1% compared to the same quarter of 2021.
Business operating income rose by 15.0% to EUR2.7bn, with business earnings per share (EPS) of EUR1.71 for the quarter, up 17.4%. EPS for the full year increased 17.1% to EUR8.26.
Sanofi reaffirmed its target to achieve Dupixent sales of EUR10bn in 2023, up from EUR8.29bn in 2022.
The strong demand for Dupixent is expected to be partly offset by generic competition for multiple sclerosis drug Aubagio this year.
For the whole of 2023, the company anticipates EPS to grow by a "low single digit" percentage.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling